Myeloma NZ

Chimeric antigen receptor (CAR) T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell...

Promising clinical trial data have highlighted advances in the treatment of mantle cell lymphoma (MCL), but an important next step is applying this...

Researchers from the Icahn School of Medicine at Mount Sinai say they have developed a RNA and DNA sequencing platform that benefits late-stage and...

Lenalidomide maintenance improved PFS and OS among patients with newly diagnosed multiple myeloma compared with other maintenance treatments,...

A high level of resilience—or a person’s ability to adapt to adversity—was associated with a better mental and physical health-related quality of...

Survival outcomes in “real world” practice may differ among nontransplant patients with multiple myeloma who receive routine care compared with...

New investigational therapies in the pipeline that address multiple myelomainclude both small-molecule and immunotherapeutic approaches — and in...

When patients with multiple myeloma become refractory to lenalidomide (Revlimid) or bortezomib (Velcade), or have penta-refractory disease, there...

Chimeric antigen receptor T-cell therapy, also known as CAR T-cell therapy, is approved for two indications — relapsed or refractory large B-cell...

INVITATION Patient Seminar: From 45 South - The Otago Myeloma Research Trust Presented by Dr Ian Morrison on 1 August, 5.30 at BNZ Partners Centre,...

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some...